|Place of Origin:||China|
|Certification:||GMP, ISO 9001, USP|
|Model Number:||CAS 57-63-6|
|Minimum Order Quantity:||Free samples Available|
|Packaging Details:||as your required|
|Delivery Time:||3-7 working days|
|Payment Terms:||Western Union, MoneyGram, T/T, Bitcoin|
|Supply Ability:||500-1000 kg / month|
|Appearance:||White To Creamy White Crystalline Powder||Biological Half-life:||7–36 Hours|
|Chemical Name:||(17α)-19-Norpregna-1,3,5(10)-trien-20-yne-3,17β-diol||Bioavailability ::||38–48%|
steroid powder source,
build muscle steroids
Ethinyl Estradiol Raw Steroid Powders for the Treatment of Female Hypogonadism
CAS Number 57-63-6
Molar mass :296.403 g/mol
Biological half-life :7–36 hours
Ethinyl estradiol (EE) (USP) (former brand name Estinyl), or ethinylestradiol (INN, USAN, JAN), also spelled as ethinylœstradiol (BAN) and also known as 17α-ethynylestra-1,3,5(10)-triene-3,17β-diol, is a synthetic, steroidal estrogen. It is a derivative of estradiol, the major endogenous estrogen in humans; specifically, EE is 17α-ethynylestradiol. EE is an orally active estrogen used in almost all formulations of combined oral contraceptives (COCs), being nearly the exclusive estrogen used for this purpose.
As Estinyl, EE was formerly used for hormone replacement therapy in menopause and the treatment of female hypogonadism, loss of menstruation, dysmenorrhea, acne, prostate cancer, and breast cancer.
However, in more recent times, EE is mainly used in COCs. In contraception, due to concerns of unopposed estrogen action and the possible increased risk of endometrial cancer that accompanies this, EE is formulated in combination with progestins. EE is little used in menopausal hormone replacement therapy.
EE has been used at very high dosages (1–2 mg/day) in the treatment of prostate cancer.
EE should be avoided in women with a history of or known susceptibility to thrombosis (blood clots), particularly venous thromboembolism (VTE).
Due to risk of cholestatic hepatotoxicity, it is widely considered that COCs containing EE should be avoided in women with a history of cholestasis of pregnancy, hepatic tumors, active hepatitis, and familial defects in biliary excretion.
Side effects of EE are the same as for other estrogens and include breast tenderness, headache, fluid retention (bloating), nausea, dizziness, and weight gain.The estrogen component of oral contraceptives, which is almost always EE, can cause breast tenderness and fullness
|Estrogen||Hot flashes||FSH||HDL cholesterol||SHBG||CBG||Angiotensinogen|
|Hot flashes = clinical relief of hot flashes; FSH = suppression of FSH levels; HDL cholesterol, SHBG, CBG,
and angiotensinogen = increase in the serum levels of these hepatic proteins.
Any needs, please contact me